{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:58:08Z","timestamp":1791903488250,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["P30-E013508"],"award-info":[{"award-number":["P30-E013508"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jsbmb.2019.01.001","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T19:00:37Z","timestamp":1547233237000},"page":"105283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: Head to head comparison with other advanced AKR1C3 targeted therapeutics"],"prefix":"10.1016","volume":"192","author":[{"given":"Phumvadee","family":"Wangtrakuldee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adegoke O.","family":"Adeniji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzhu","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buddha","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry M.","family":"Twenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler F.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor M.","family":"Penning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsbmb.2019.01.001_bib0005","first-page":"293","article-title":"Studies on prostatic cancer 1. Effect of castration, estrogen and androgen injection on serum phosphatases in metatstatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0010","first-page":"1163","article-title":"Two principles in endocrine therapy of cancers: hormone deprival and hormone interference","volume":"25","author":"Huggins","year":"1965","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.jsbmb.2019.01.001_bib0015","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0149-2918(96)80215-3","article-title":"Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer","volume":"18","author":"Sharifi","year":"1996","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0020","series-title":"Surveilance, Epidemiology, and End Results Program","author":"SEER","year":"2014"},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0025","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1158\/1078-0432.CCR-08-2660","article-title":"Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer","volume":"15","author":"Knudsen","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0030","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.tem.2010.01.002","article-title":"Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer","volume":"21","author":"Knudsen","year":"2010","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0035","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase 1 clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"28","author":"Attard","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0040","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","article-title":"Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer","volume":"27","author":"Attard","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.jsbmb.2019.01.001_bib0045","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1200\/JCO.2009.25.9259","article-title":"Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer","volume":"28","author":"Danila","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0050","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","article-title":"Prostate cancer foundation\/department of defense prostate cancer clinical trials consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study","volume":"375","author":"Scher","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0055","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0060","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1158\/1078-0432.CCR-11-0728","article-title":"Resistance to CYP17A1 inhibition with abiraterone in castrate-resistance prostate cancer: induction of steroidogenesis and androgen receptor splice variants","volume":"17","author":"Mostaghel","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0065","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jsbmb.2015.05.010","article-title":"Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC)","volume":"153","author":"Penning","year":"2015","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0070","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/1535-7163.MCT-16-0186","article-title":"Inhibition of AKR1C3 activation overcomes resistance to abiraterone in advanced prostate cancer","volume":"16","author":"Liu","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0075","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1158\/0008-5472.CAN-14-3080","article-title":"Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0080","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jsbmb.2011.12.012","article-title":"Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5\u03b1-reductase inhibitor finasteride","volume":"130","author":"Byrns","year":"2012","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0085","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1042\/bj3510067","article-title":"Human 3a-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones","volume":"351","author":"Penning","year":"2000","journal-title":"Biochem. J."},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0090","first-page":"1971","article-title":"Expression and characterization of recombinant type 2 3a-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3a\/17b-HSD activity and cellular distribution","volume":"11","author":"Lin","year":"1997","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0095","doi-asserted-by":"crossref","first-page":"13728","DOI":"10.1073\/pnas.1107898108","article-title":"Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer","volume":"108","author":"Chang","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0100","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.tem.2004.09.004","article-title":"The backdoor pathway to dihydrotestosterone","volume":"15","author":"Auchus","year":"2004","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0105","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.1021\/acs.jmedchem.6b00160","article-title":"Discovery of (R)-2-(6-methoxynaphthalen-2-yl)butanoic acid as a potent and selective aldo-keto reductase 1C3 inhibitor","volume":"59","author":"Adeniji","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0110","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.bmcl.2011.01.010","article-title":"Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17\u03b2-hydroxysteroid dehydrogenase (AKR1C3)","volume":"21","author":"Adeniji","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0115","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1021\/jm201547v","article-title":"Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17\u03b2-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships","volume":"55","author":"Adeniji","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0120","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s10637-014-0130-5","article-title":"In vitro and in vivo characterization of ASP9521: a novel selective, orally bioavailable inhibitor of 17b-hydroxysteroid dehydrogenase type 5 (17b-HSD5; AKR1C3)","volume":"32","author":"Kikuchi","year":"2014","journal-title":"Invest. New Drugs"},{"issue":"6","key":"10.1016\/j.jsbmb.2019.01.001_bib0125","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1021\/jm3017656","article-title":"Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (type 5 17b-hydroxysteroid dehydrogenase\/prostaglandin F synthase) in castrate-resistant prostate cancer","volume":"56","author":"Liedtke","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0130","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.1158\/1078-0432.CCR-13-1151","article-title":"Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth","volume":"19","author":"Yepuru","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0135","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1016\/j.bmcl.2012.03.085","article-title":"Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer","volume":"22","author":"Chen","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0140","series-title":"Preparation of Isoquinoline Compounds As Aldo-keto Reductase Subfamily 1C3 (AKR1C3) Inhibitors for Treating Cancer and Other Diseases","author":"Dalton","year":"2013"},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0145","article-title":"Discovery of ASP9521, a novel, potent, selective 17\u03b2-HSD5 inhibitor","author":"Watanabe","year":"2014","journal-title":"Abstract In 246th American Chemical Society Meeting"},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0150","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0155","doi-asserted-by":"crossref","first-page":"6781","DOI":"10.1021\/bi972725u","article-title":"Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione","volume":"37","author":"Burczynski","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0160","doi-asserted-by":"crossref","first-page":"23368","DOI":"10.1074\/jbc.M112.344671","article-title":"A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes","volume":"287","author":"Cherian","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0165","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1210\/en.2002-0032","article-title":"Human type 3 3a-hydroxysteroid dehydrogenase (AKR1C2) and androgen metabolism in prostate cells","volume":"144","author":"Rizner","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0170","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s10637-014-0101-x","article-title":"Safety, tolerability and anti-tumor activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I\/II study","volume":"32","author":"Loriot","year":"2014","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0175","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nature14406","article-title":"Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer","volume":"523","author":"Li","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0180","series-title":"ASCO Annual Meeting","article-title":"ASP9521, a novel, selective, orally bioavailable AKR1C3 (type 5 17b-hydroxysteroid dehydrogenase) inhibitor: in vitro and in vivo characterization","author":"Kikuchi","year":"2013"},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0185","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1073\/pnas.0500381102","article-title":"Structural basis for antagonism and resistance of bicalutamide in prostate cancer","volume":"102","author":"Bohl","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jsbmb.2019.01.001_bib0190","doi-asserted-by":"crossref","first-page":"37747","DOI":"10.1074\/jbc.M507464200","article-title":"Structural basis for accommodation of nonsteroidal ligands in the androgen receptor","volume":"280","author":"Bohl","year":"2005","journal-title":"J. Biol. Chem."}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076018307209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076018307209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:03:22Z","timestamp":1760745802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076018307209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":38,"alternative-id":["S0960076018307209"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2019.01.001","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: Head to head comparison with other advanced AKR1C3 targeted therapeutics","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2019.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105283"}}